Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus

Wiley - Tập 33 Số 5 - Trang 634-643 - 1990
E. J. ter Borg1, Gerda Horst2, E. J. Hummel2, P. C. Limburg2, Cees G. M. Kallenberg2
1Department of Internal Medicine, University Hospital, Groningen, The Netherlands
2Department of Internal Medicine, Divisions of Clinical Immunology and Rheumatology, University Hospital, Groningen, The Netherlands.

Tóm tắt

AbstractTo evaluate the predictive power of changes in levels of antibodies to double‐stranded DNA (anti‐dsDNA) as a predictor of disease exacerbations in systemic lupus erythematosus (SLE), we performed a prospective study on 72 unselected patients with SLE (mean duration of study 18.5 months, range 6–35 months). Patients were seen at least once every 3 months, and disease activity was scored according to a specific protocol. Plasma samples were obtained at least once every month and were assessed for anti‐dsDNA antibody (by the Crithidia luciliae assay, an enzymelinked immunosorbent assay [ELISA], and the Farr assay) and for complement components C3 and C4. Twenty‐seven of 33 disease exacerbations observed during the study period were accompanied by a positive test result for anti‐dsDNA antibody (27 by the Farr assay, 19 by the C luciliae assay, and 23 by the ELISA). Twenty‐four of these exacerbations were preceded by a significant increase in anti‐dsDNA antibody levels (23 by the Farr assay, 12 by the C luciliae assay, and 17 by the ELISA). The first observance of a significant increase in anti‐dsDNA antibody levels preceded the exacerbation by 8–10 weeks. Significant increases in anti‐dsDNA antibody levels not followed by an exacerbation were observed in 5 cases by the Farr assay, in 7 cases by the C luciliae assay, and in 3 cases by the ELISA; however, in 3 cases, 2 cases, and 1 case, respectively, these increases were followed by an increase in disease activity that did not fulfill the criteria for an exacerbation. Serial measurement of anti‐dsDNA antibody levels was more sensitive for predicting exacerbations than was measurement of C3 and/or C4 levels (P < 0.03). Serial assessment of anti‐dsDNA antibody levels, especially by the Farr assay, is a sensitive and reasonably specific method for predicting disease exacerbations in SLE.

Từ khóa


Tài liệu tham khảo

10.1016/S0065-2776(08)60836-6

10.1097/00005792-198601000-00003

10.1056/NEJM196909252811304

10.1136/ard.36.2.157

10.1002/art.1780220402

10.1136/ard.30.3.259

10.1084/jem.134.1.294

10.1056/NEJM196803072781004

10.3109/03009747509095629

10.1097/00005792-198105000-00004

10.1136/ard.45.4.314

10.1002/art.1780270203

10.1016/0002-9343(79)90529-1

10.1146/annurev.me.25.020174.001053

Smeenk R, 1982, Avidity of antibodies to dsDNA: comparison of IFT on Crithidia luciliae, Farr assay, and PEG assay., J Immunol, 128, 73, 10.4049/jimmunol.128.1.73

10.1016/0002-9343(73)90121-6

10.1002/art.1780220304

10.1136/ard.45.5.359

10.1136/ard.34.5.444

10.1002/art.1780280810

10.1002/art.1780251101

10.1002/art.1780310701

Kallenberg CGM, 1983, B‐cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis., Clin Exp Immunol, 53, 371

10.1111/j.1749-6632.1975.tb29197.x

10.1136/ard.47.9.740

10.1172/JCI108118

Wallace DJ, 1987, Lupus Erythematosus

10.1136/ard.47.10.820

10.1136/ard.46.6.448

10.1002/art.1780280411

10.1172/JCI108892

10.1136/ard.47.9.717

10.1172/JCI112508

Morrow WJW, 1982, Useful laboratory measurements in the management of systemic lupus erythematosus., Q J Med, 202, 125

Cameron JS, 1976, Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations., Clin Exp Immunol, 25, 418

Thông tin
Thông tin xuất bản

Wiley

Tập 33 Số 5

634-643

Thông tin tác giả